Clinical Trial Update: Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating Imipenem/Cilastatin/Relebactam for carbapenem-resistant Enterobacteriaceae infections has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibiotic-resistant Infection
• Carbapenem-resistant Enterobacteriaceae Infection
• Gram-negative Bacterial Infection

Drugs mentioned

• Imipenem/Cilastatin/Relebactam (imipenem/cilastatin/relebactam)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Carbapenem-Resistant Enterobacteriaceae Infection, KPC | Phase 4 | Status: WITHDRAWN